Pentti J Tienari

List of Publications by Year
in descending order

78	10,686	186265 28	69250 77
papers	citations	h-index	g-index

78	78	78	12886
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effectiveness of clinical exome sequencing in adult patients with difficultâ€toâ€diagnose neurological disorders. Acta Neurologica Scandinavica, 2022, 145, 63-72.	2.1	16
2	Primary ageâ€related tauopathy in a Finnish populationâ€based study of the oldest old (Vantaa 85+). Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	6
3	Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	36
4	Immune response to a conserved enteroviral epitope of the major capsid VP1 protein is associated with lower risk of cardiovascular disease. EBioMedicine, 2022, 76, 103835.	6.1	2
5	ALS in Finland. Neurology: Genetics, 2022, 8, e665.	1.9	11
6	Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients. EBioMedicine, 2021, 64, 103211.	6.1	11
7	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
8	Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays. Clinical Biochemistry, 2021, 90, 34-39.	1.9	9
9	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
10	Alpha-synuclein pathology of olfactory bulbs/peduncles in the Vantaa85+â€‰cohort exhibit two divergent patterns: a population-based study. Acta Neuropathologica, 2021, 142, 777-780.	7.7	8
11	A Novel Genetic Marker for the C9orf72 Repeat Expansion in the Finnish Population. Journal of Alzheimer's Disease, 2021, 83, 1325-1332.	2.6	6
12	APOE Îµ4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study. Acta Neuropathologica Communications, 2021, 9, 199.	5.2	55
13	CD8+ cell somatic mutations in multiple sclerosis patients and controlsâ€”Enrichment of mutations in STAT3 and other genes implicated in hematological malignancies. PLoS ONE, 2021, 16, e0261002.	2.5	15
14	Putative risk alleles for LATEâ€NC with hippocampal sclerosis in populationâ€representative autopsy cohorts. Brain Pathology, 2020, 30, 364-372.	4.1	17
15	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
16	Carriership of two copies of C9orf72 hexanucleotide repeat intermediate-length alleles is a risk factor for ALS in the Finnish population. Acta Neuropathologica Communications, 2020, 8, 187.	5.2	16
17	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	38
18	Vascular and Alzheimer Disease in Dementia. Annals of Neurology, 2020, 87, 788-788.	5.3	6

#	Article	IF	Citations
19	Finnish neuroscience from past to present. European Journal of Neuroscience, 2020, 52, 3273-3289.	2.6	2
20	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
21	Multiple sclerosis in Finland 2018â€”Data from the national register. Acta Neurologica Scandinavica, 2019, 140, 303-311.	2.1	26
22	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
23	The clinical spectrum and prognosis of idiopathic acute optic neuritis: A longitudinal study in Southern Finland. Multiple Sclerosis and Related Disorders, 2019, 35, 215-220.	2.0	2
24	Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85+. Acta Neuropathologica, 2019, 138, 771-782.	7.7	46
25	Oligogenic basis of sporadic ALS. Neurology: Genetics, 2019, 5, e335.	1.9	15
26	Contributions of vascular and Alzheimer's disease pathology to dementia. Alzheimer's and Dementia, 2019, 15, 1004-1005.	0.8	3
27	C9orf72 hexanucleotide repeat length in older population: normal variation and effects on cognition. Neurobiology of Aging, 2019, 84, 242.e7-242.e12.	3.1	16
28	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and Î±â€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
29	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
30	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
31	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
32	APOE É›4, rs405509, and rs440446 promoter and intron-1 polymorphisms and dementia risk in a cohort of elderly Finnsâ€Helsinki Birth Cohort Study. Neurobiology of Aging, 2019, 73, 230.e5-230.e8.	3.1	2
33	Alzheimer risk loci and associated neuropathology in a population-based study (Vantaa 85+). Neurology: Genetics, 2018, 4, e211.	1.9	16
34	Genetics of dementia in a Finnish cohort. European Journal of Human Genetics, 2018, 26, 827-837.	2.8	6
35	Hippocampal Sclerosis in the Oldest Old: A Finnish Population-Based Study. Journal of Alzheimer's Disease, 2018, 63, 263-272.	2.6	20
36	Heterozygous TYROBP deletion (PLOSLFIN) is not a strong risk factor for cognitive impairment. Neurobiology of Aging, 2018, 64, 159.e1-159.e4.	3.1	3

#	Article	IF	Citations
37	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology, 2018, 90, 849-851.	1.1	32
38	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
39	Common origin of the gelsolin gene variant in 62 Finnish AGel amyloidosis families. European Journal of Human Genetics, 2018, 26, 117-123.	2.8	6
40	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
41	Phosphorylation of Parkin at serine 65 is essential for its activationin vivo. Open Biology, 2018, 8, 180108.	3.6	81
42	Incidence and Mimickers of Acute Idiopathic Optic Neuritis: Analysis of 291 Consecutive Patients from Southern Finland. Ophthalmic Epidemiology, 2018, 25, 386-391.	1.7	4
43	Melatonin receptor type 1A gene linked to Alzheimerâ€™s disease in old age. Sleep, 2018, 41, .	1.1	30
44	Cardiovascular risk factors and glucose tolerance in midlife and risk of cognitive disorders in old age up to a 49-year follow-up of the Helsinki businessmen study. Annals of Medicine, 2017, 49, 462-469.	3.8	12
45	Age-related penetrance of the C9orf72 repeat expansion. Scientific Reports, 2017, 7, 2116.	3.3	102
46	Magnetic Resonance Imaging of Internal Jugular Veins in Multiple Sclerosis: Interobserver Agreement and Comparison with Doppler Ultrasound Examination. Annals of Vascular Surgery, 2017, 42, 84-92.	0.9	7
47	Populationâ€based analysis of pathological correlates of dementia in the oldest old. Annals of Clinical and Translational Neurology, 2017, 4, 154-165.	3.7	29
48	A novel class of somatic mutations in blood detected preferentially in CD8 + cells. Clinical Immunology, 2017, 175, 75-81.	3.2	35
49	Genetic risk factors in Finnish patients with Parkinson's disease. Parkinsonism and Related Disorders, 2017, 45, 39-43.	2.2	19
50	SNCA mutation p.Ala53Glu is derived from a common founder in the Finnish population. Neurobiology of Aging, 2017, 50, 168.e5-168.e8.	3.1	7
51	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
52	A Novel Loss-of-Function GRN Mutation p.(Tyr229*):â€ŠClinical and Neuropathological Features. Journal of Alzheimer's Disease, 2016, 55, 1167-1174.	2.6	5
53	Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 142-149.	1.3	41
54	APOE and aging-related cognitive change in a longitudinal cohort of men. Neurobiology of Aging, 2016, 44, 151-158.	3.1	8

#	Article	IF	Citations
55	Cohort Profile: The Helsinki Businessmen Study (HBS). International Journal of Epidemiology, 2016, 45, 1074-1074h.	1.9	39
56	Generation of <scp>GFAP::GFP</scp> astrocyte reporter lines from human adult fibroblastâ€derived i<scp>PS</scp> cells using zincâ€finger nuclease technology. Glia, 2016, 64, 63-75.	4.9	26
57	Genomeâ€wide association study of neocortical Lewyâ€related pathology. Annals of Clinical and Translational Neurology, 2015, 2, 920-931.	3.7	25
58	Exome and regulatory element sequencing of neuromyelitis optica patients. Journal of Neuroimmunology, 2015, 289, 139-142.	2.3	6
59	The Phenotype of the C9ORF72 Expansion Carriers According to Revised Criteria for bvFTD. PLoS ONE, 2015, 10, e0131817.	2.5	32
60	Genome-Wide Analysis of the Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 1123.	9.0	69
61	Suspected YF-AND after yellow fever vaccination in Finland. Journal of Clinical Virology, 2014, 61, 444-447.	3.1	5
62	A novel Î±-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiology of Aging, 2014, 35, 2180.e1-2180.e5.	3.1	396
63	The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation. Neurobiology of Aging, 2014, 35, 1780.e13-1780.e17.	3.1	3
64	P1-128: C9ORF72 EXPANSION DOES NOT HAVE EFFECTS ON CSF TDP-43 LEVELS IN FTLD PATIENTS. , 2014, 10, P347-P347.		0
65	Attrition in a 30-year follow-up of a perinatal birth risk cohort: factors change with age. PeerJ, 2014, 2, e480.	2.0	25
66	TNFRSF1A in multiple sclerosis: A tale of soluble receptors and signaling cascades. Neurology, 2013, 81, 1886-1888.	1.1	6
67	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039
68	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
69	Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurology, The, 2010, 9, 978-985.	10.2	236
70	The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a metaâ€analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 648-655.	1.7	50
71	Geographical variation of medicated parkinsonism in Finland during 1995 to 2000. Movement Disorders, 2008, 23, 1024-1031.	3.9	12
72	Multiple sclerosis in G: Genes and geography. Clinical Neurology and Neurosurgery, 2006, 108, 223-226.	1.4	3

#	Article	IF	Citations
73	Multiple sclerosis in western Finland: evidence for a founder effect. Clinical Neurology and Neurosurgery, 2004, 106, 175-179.	1.4	15
74	Association of lipoprotein base Ser447Ter polymorphism with brain infarction: a population-based neuropathological study. Annals of Medicine, 2001, 33, 486-492.	3.8	36
75	Genetic association of ?2-macroglobulin with Alzheimer's disease in a Finnish elderly population. Annals of Neurology, 1999, 46, 382-390.	5.3	98
76	Distinct sites of intracellular production for Alzheimer's disease AÎ²40/42 amyloid peptides. Nature Medicine, 1997, 3, 1016-1020.	30.7	716
77	A putative vulnerability locus to multiple sclerosis maps to 5p14â€“p12 in a region syntenic to the murine locus Eae2. Nature Genetics, 1996, 13, 477-480.	21.4	200
78	Multiple Sclerosis: Multiple Etiologies, Multiple Genes?. Annals of Medicine, 1994, 26, 259-269.	3.8	13